Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026
Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026
截至2024年3月31日，Cartesian Therapeutics約1.048億美元的現金、現金等價物和限制性現金，預計將爲2026年下半年的計劃運營提供支持
Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026
截至2024年3月31日，Cartesian Therapeutics約1.048億美元的現金、現金等價物和限制性現金，預計將爲2026年下半年的計劃運營提供支持
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。